Acuta Capital Partners LLC Lowers Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Acuta Capital Partners LLC trimmed its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 29.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,500 shares of the biotechnology company's stock after selling 55,500 shares during the quarter. Rocket Pharmaceuticals accounts for 1.7% of Acuta Capital Partners LLC's holdings, making the stock its 19th biggest holding. Acuta Capital Partners LLC owned 0.15% of Rocket Pharmaceuticals worth $1,691,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Boxer Capital Management LLC bought a new position in Rocket Pharmaceuticals in the fourth quarter valued at approximately $18,428,000. Northern Trust Corp increased its holdings in shares of Rocket Pharmaceuticals by 14.2% during the fourth quarter. Northern Trust Corp now owns 663,152 shares of the biotechnology company's stock worth $8,336,000 after buying an additional 82,316 shares in the last quarter. Tudor Investment Corp ET AL lifted its stake in shares of Rocket Pharmaceuticals by 85.4% in the 4th quarter. Tudor Investment Corp ET AL now owns 31,125 shares of the biotechnology company's stock valued at $391,000 after acquiring an additional 14,338 shares during the last quarter. Boothbay Fund Management LLC boosted its stake in shares of Rocket Pharmaceuticals by 20.6% during the fourth quarter. Boothbay Fund Management LLC now owns 52,130 shares of the biotechnology company's stock valued at $655,000 after purchasing an additional 8,894 shares in the last quarter. Finally, Virtus ETF Advisers LLC grew its holdings in shares of Rocket Pharmaceuticals by 40.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,656 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 1,628 shares during the last quarter. Institutional investors own 98.39% of the company's stock.

Insider Transactions at Rocket Pharmaceuticals

In related news, CFO Aaron Ondrey sold 7,489 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $5.29, for a total transaction of $39,616.81. Following the sale, the chief financial officer now owns 129,650 shares of the company's stock, valued at approximately $685,848.50. This trade represents a 5.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Gaurav Shah purchased 20,000 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Thursday, April 10th. The stock was acquired at an average price of $5.08 per share, for a total transaction of $101,600.00. Following the transaction, the chief executive officer now directly owns 792,680 shares of the company's stock, valued at $4,026,814.40. The trade was a 2.59 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 28.50% of the company's stock.

Rocket Pharmaceuticals Price Performance

NASDAQ:RCKT traded up $0.38 during trading hours on Wednesday, hitting $6.69. The stock had a trading volume of 2,038,929 shares, compared to its average volume of 1,383,885. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals, Inc. has a one year low of $4.55 and a one year high of $26.98. The firm has a market capitalization of $714.29 million, a price-to-earnings ratio of -2.45 and a beta of 1.02. The company has a 50 day simple moving average of $7.27 and a two-hundred day simple moving average of $10.87.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.06. Research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on RCKT. The Goldman Sachs Group decreased their price target on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Scotiabank increased their price target on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, March 3rd. Chardan Capital decreased their price target on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating for the company in a research note on Friday, February 28th. BMO Capital Markets assumed coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $42.00 price target on shares of Rocket Pharmaceuticals in a report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.